Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VAR-101
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Varian Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Varian Bio’s lead drug candidate, VAR-101, is being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 31, 2021
Lead Product(s) : VAR-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Varian Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition